Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib (M6620) plus topotecan in relapsed platinum‑resistant small-cell lung cancer
jRCT2031210191Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of berzosertib and topotecan in small cell lung cancer (SCLC) and advanced nonhematological malignancy (2 arms), sponsored by Merck KGaA. Primary endpoints: Objective response rate (IRC-assessed RECIST v1.1), Dose-limiting toxicities and 2 more. Started Aug 2021; status: completed.
02
Drugs
berzosertibtopotecan
03
Conditions
small cell lung cancer (SCLC)advanced nonhematological malignancy
Beyond the preview
Go deeper on jRCT2031210191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210191.